What other stocks do shareholders of (RPTP) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (RPTP) investors own include BioCryst Pharmaceuticals (BCRX) , OPKO Health (OPK) , Freeport-McMoRan (FCX) , Novavax (NVAX) , Achillion Pharmaceuticals (ACHN) , Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR) .

Notice: This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RPTP

(RPTP) (RPTP) Stock Price, News & Analysis

Compare

Get (RPTP) alerts:

About (RPTP) Stock (NASDAQ:RPTP)

Advanced Chart

Ad Chaikin Analytics

Prepare for an election day stock surprise

During his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential elections. But that's nothing compared to his new election stock warning.

For all the details, including the #1 stock to SELL before Election Day, click here.

Get (RPTP) alerts:

Key Stats

Today's Range: $9.00
▼
$9.00
50-Day Range: N/A
52-Week Range: $2.94
▼
$9.05
Volume: N/A
Average Volume: 1.42 million shs
Market Capitalization: N/A
P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A
Consensus Rating: N/A

Company Overview

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

RPTP Stock News Headlines

National Bank of Canada Pref Share NA.PR.C

May 18, 2024 | morningstar.com

Key Insights into LAR-RPTP's Synaptic Regulation via Microexon Molecular Codes

March 30, 2024 | msn.com

[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

September 27, 2024 | Paradigm Press (Ad)

Research suggests fine-tuning of specific excitatory synapse traits could lead to new brain disease treatments

March 29, 2024 | msn.com

Auckland Council bids to untangle transport from government

August 17, 2023 | msn.com

Amigo scrambles for survival as £45m emergency cash talks fail

March 10, 2023 | msn.com

The Arts Council of the Brazos Valley is hosting a Boots & BBQ Fundraiser to help the local community

February 23, 2023 | msn.com

RPTP Stock Analysis - Frequently Asked Questions

: Based on aggregate information from My MarketBeat watchlists, some other companies that (RPTP) investors own include BioCryst Pharmaceuticals (BCRX), OPKO Health (OPK), Freeport-McMoRan (FCX), Novavax (NVAX), Achillion Pharmaceuticals (ACHN), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR).

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:RPTP
CUSIP: 75382F10
CIK: 1070698
Web: www.horizonpharma.com
Phone: +1-415-4086200
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:RPTP) was last updated on 9/27/2024 by MarketBeat.com Staff

From Our Partners